Posts by Sam

Eli Lilly Seeks FDA Approval for Experimental Alzheimer’s Drug

During its third-quarter earnings report, Eli Lilly announced that it’s pursuing accelerated approval for the investigational Alzheimer’s drug donanemab ― and that it also plans to evaluate the therapy compared to Biogen’s Aduhelm (aducanumab) in a head-to-head study. Source: Drug Industry Daily

Read More

AstraZeneca Continues Its Hit Parade With Yet Another Imfinzi Win

AstraZeneca has scored another win with Imfinzi (durvalumab), showing that the checkpoint inhibitor in combination with standard chemotherapy improved both overall and progression-free survival for patients with advanced biliary tract cancer (BTC), a rare, aggressive disease with extremely low 5-year survival rates. Source: Drug Industry Daily

Read More